Andrew P Schachat

Learn More
AIM To evaluate efficacy and safety of intravitreal aflibercept injection (IAI) in subjects who were previously treated with ranibizumab and/or bevacizumab for active exudative age-related macular degeneration (AMD). METHODS Patients (n=26) were enrolled in a 12-month prospective, interventional, single arm, investigator-initiated study with planned(More)
A 45-year-old man with extensive myelinated retinal nerve fibers had an attack of anterior ischemic optic neuropathy. Serial fundus photographs documented the loss of myelin. Visual acuity in the affected eye decreased to 6/90 (20/300) and color perception was markedly reduced. The visual fields in the affected eye showed dense superior and inferior arcuate(More)
SUMMARY STATEMENT In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline. PURPOSE Switching therapies in neovascular age-related macular degeneration (AMD) may offer an advantage for some(More)
Visualization of the vitreous during a closed anterior vitrectomy is difficult. We have recently begun to use an irrigating endo-illuminator in conjunction with the Ocutome to better visualize the clear vitreous during an anterior vitrectomy, and have used it in four different situations. We believe this technique is well suited to the general(More)
  • 1